

## Ahead of FY12 growth forecast

Primary Health Properties has acquired Apollo Medical Partners (AMP) in a £10.2m corporate transaction which adds 14 assets valued at £62.3m to its portfolio; it also assumed £49.8m of debt. It paid £4.2m in cash and 1.23m in shares on completion including transaction costs; another £1.8m is due on delivery of assets under construction. That builds on £29.5m of acquisitions and commitments between 1 July and the 15 November IMS. AMP was part of a reported £106m of deals in solicitors' hands at that date and followed a £3.6m asset purchase earlier this month. PHP now holds 183 assets, a total value of £643.3m including forward funding commitments, with a £38.9m contracted annual rent roll. Total available debt post AMP is £508.5m, with c £400m drawn or committed. We have adjusted our forecasts for the new assets, higher FY12 portfolio growth assumptions of £72m – previously £60m – and PHP's expectation that it will refinance AMP's debt at c 4% fixed in early FY13.

Year end	Revenue (£m)	PBT* (£m)	EPS* (p)	DPS (p)	P/E (x)	EPRA NAV (p)
12/10	26.9	9.1	14.7	17.5	5.1	311
12/11	30.7	9.7	14.6	18.0	5.3	319
12/12e	33.6	8.0	11.1	18.5	5.4	315
12/13e	41.0	11.2	14.7	19.0	5.6	316

\*PBT and EPS are normalised, excluding intangible amortisation, exceptional items and share-based payments.

### AMP acquisition secures 14 modern assets

AMP's assets were acquired for £64.6m including £0.6m in costs, giving a 5.9% net initial rental yield. As the portfolio was independently valued at £62.3m, the purchase results in a £2.3m or 3p/share NAV reduction. The £49.8m of assumed debt has on average c 18 years to maturity. Of AMP's 11 complete and let assets, 10 were built in the past five years. The three under construction expected to complete between February and August 2013. Total rent roll on the completed portfolio will be £3.8m pa, with a 5.9% net initial yield derived from GPs/PCTs/NHS bodies (c 92% of rents) and pharmacy operators with an 18-year weighted average unexpired lease length.

### Valuation: Deal improves FY13 dividend cover

The 5.6% prospective yield is a key attraction, based on another 0.5p/share dividend increase in FY13. Although not fully covered by earnings, the latest deal should help narrow the gap in FY13 and push up cover to 78% from 73%, subject to timing and terms of debt refinance. PHP's ability to continue to secure acquisitions on an EPS enhancing basis is encouraging. Assets remain available at a material positive gap between the net initial rental yield and debt finance cost. PHP will seek to reset the rate on, or refinance assumed debt in early FY13 and expects to achieve an all-in funding cost c 200bps below the 5.9% initial net yield. The purchase price included an allowance for part of any potential cost to reset the debt cost. We have maintained our £50m forecast for FY13 acquisitions, which looks conservative. PHP has a pipeline above that and c £109m of undrawn facilities post this acquisition, although a £27m debt facility, which matures at the end of January 2013, may be refinanced from existing facilities.

## Real estate

21 December 2012

Price 341.25p

Market cap £255m

Shares in issue	76m
Free float	94%
Code	PHP
Net debt as at 30 Jun 12 (£m)	300
Primary exchange	LSE
Other exchanges	N/A

### Share price performance



%	1m	3m	12m
Abs	3.6	(1.2)	9.4
Rel (local)	(0.1)	(1.5)	(2.8)
52-week high/low		350p	310p

### Business description

Primary Health Properties invests in primary healthcare property in the UK, principally let to GPs, PCTs and other NHS entities backed by the UK government. This tenant profile provides an exceptionally secure rental outlook.

### Next events

February 2013 Final results

### Analysts

Roger Leboff +44 (0)20 3077 5700  
Martyn King +44 (0)20 3077 5745

[property@edisoninvestmentresearch.co.uk](mailto:property@edisoninvestmentresearch.co.uk)

[Edison profile page](#)

## Revised forecasts: Improved dividend cover post acquisitions

We set out our amended forecasts below, adjusted for recent acquisitions. Downward adjustment in FY12 profit and earnings reflect the fact that although the scale of portfolio growth is in line with expectations, the timing of commitments is slower than we had built into our previous forecasts.

Of most significance for the valuation is that recent acquisitions result in a better than anticipated improvement in dividend cover during FY13, reflecting the full year impact of larger than expected portfolio growth.

PHP is committed to restoring full cover over the next few years, which will require both material further portfolio growth and access to debt and equity on sufficiently attractive terms to maintain the gap between net initial yields on acquisition (c 5.8-6.0%), cost of debt and equity and incremental management costs.

**Exhibit 1: Changes in forecasts – P&L**

	Revenue (£m)		%	PBT (£m)		%	EPS (p)		%	Dividend cover (%)		%
	Old	New		Old	New		Old	New		Old	New	
FY11	30.7	-	-	9.7	-	-	14.6	-	-	81%	-	-
FY12e	34.2	33.5	-2%	9.0	8.0	-11%	12.5	11.1	-11%	68%	60%	-11%
FY13e	38.1	41.0	+8%	10.4	12.0	+15%	13.9	14.8	+7%	73%	78%	+7%

Source: Edison Investment Research estimates

We have reduced our NAV/share forecasts by 3p for each for this year and next, reflecting the impact of the AMP acquisition.

We have assumed £81.3 m of portfolio acquisitions this year, and £50m during FY13. With undrawn facilities available no further equity issues are currently built into the FY13 forecast.

**Exhibit 2: Changes in forecast – net asset value**

	Net assets (£m)			%	EPRA NAV/share (p)			%
	Old	New	Change		Old	New	Change	
FY11	168.1				319			
FY12e	187.8	191.1	+2%		318	315	-1%	
FY13e	189.7	194.2	+2%		319	316	-1%	

Source: Edison Investment Research estimates

## Exhibit 3: Financial summary

	£'000s	2008	2009	2010	2011	2012e	2013e
Year end 31 December		IFRS	IFRS	IFRS	IFRS	IFRS	IFRS
<b>PROFIT &amp; LOSS</b>							
Revenue		19,691	21,332	26,915	30,676	34,325	41,493
Cost of Sales		0	0	0	0	0	0
Gross Profit		19,691	21,332	26,915	30,676	34,325	41,493
EBITDA		15,125	18,034	21,871	25,117	28,418	35,178
Operating Profit (before GW and except.)		15,125	18,034	21,871	25,117	28,418	35,178
Intangible Amortisation		0	0	0	0	0	0
Exceptionals		0	0	0	0	0	0
Other		0	0	0	312	0	0
Operating Profit		15,125	18,034	21,871	25,429	28,418	35,178
Net valuation gain on property portfolio		(17,707)	1,615	22,790	10,584	1,500	5,000
Mark to market loss on derivatives		(10,655)	1,318	(4,714)	(7,947)	(600)	0
Net Interest		(10,502)	(10,181)	(12,722)	(15,417)	(19,389)	(23,036)
Profit Before Tax (norm)		4,623	7,853	9,149	9,700	9,029	12,142
Profit Before Tax (FRS 3)		(23,739)	10,786	27,225	12,337	9,929	17,142
Tax		(160)	0	(1,550)	5	0	0
Profit After Tax (norm)		4,463	7,853	7,599	9,705	9,029	12,142
Profit After Tax (FRS 3)		(23,899)	10,786	25,675	12,342	9,929	17,142
Average Number of Shares Outstanding (m)		33.6	40.6	62.2	66.6	72.2	76.2
EPS - normalised (p)		13.3	18.4	14.7	14.6	12.5	15.9
EPS - FRS 3 (p)		(71.2)	26.6	41.3	18.5	13.7	22.5
Dividend per share (p)		16.5	17.0	17.5	18.0	18.5	19.0
Gross Margin (%)		100.0	100.0	100.0	100.0	100.0	100.0
EBITDA Margin (%)		76.8	84.5	81.3	81.9	82.8	84.8
Operating Margin (before GW and except.) (%)		76.8	84.5	81.3	81.9	82.8	84.8
<b>BALANCE SHEET</b>							
Fixed Assets		320,133	349,786	472,739	528,679	611,486	666,486
Investment properties		316,862	341,890	469,290	525,586	608,386	663,386
Development properties		282	3,496	0	0	0	0
Net inv. in fin leases/ deriv. int. Rate swaps		2,989	4,400	3,449	3,093	3,100	3,100
Current Assets		2,987	2,263	3,555	2,740	4,525	6,025
Other		454	63	555	0	0	0
Debtors		1,808	1,939	2,582	2,633	3,000	4,000
Cash		675	212	370	77	1,500	2,000
Current Liabilities		(23,597)	(20,321)	(33,241)	(36,913)	(50,700)	(24,100)
Creditors		(23,597)	(20,321)	(29,684)	(36,321)	(23,100)	(24,100)
Short term borrowings		0	0	(3,557)	(592)	(27,600)	0
Long Term Liabilities		(221,237)	(176,317)	(278,307)	(326,386)	(374,200)	(454,200)
Long term borrowings		(204,088)	(166,139)	(263,888)	(300,747)	(332,000)	(412,000)
Other long term liabilities		(17,149)	(10,178)	(14,419)	(25,639)	(42,200)	(42,200)
Net Assets		78,286	155,411	164,746	168,120	191,111	194,211
<b>CASH FLOW</b>							
Operating Cash Flow		15,799	15,951	22,801	24,025	14,730	35,178
Net Interest		(9,883)	(3,346)	(12,722)	(15,417)	(19,389)	(23,036)
Tax		0	0	0	0	0	0
Capex		0	0	0	0	0	0
Acquisitions/disposals		(49,311)	(23,413)	(70,761)	(44,589)	(81,300)	(50,000)
Financing		0	60,748	0	15,605	22,475	0
Dividends		(5,542)	(5,562)	(9,825)	(11,199)	(12,941)	(13,356)
Other		0	(6,541)	0	(2,880)	(413)	(686)
Net Cash Flow		(48,937)	37,837	(70,507)	(34,455)	(76,838)	(51,900)
Opening net debt/(cash)		155,357	203,413	165,927	267,075	301,262	358,100
HP finance leases initiated		0	0	0	0	0	0
Other - including adjustment for corporate transactions		881	(351)	(30,641)	268	20,000	0
Closing net debt/(cash)		203,413	165,927	267,075	301,262	358,100	410,000

Source: Company accounts/Edison Investment Research

**EDISON INVESTMENT RESEARCH LIMITED**

Edison Investment Research Limited (Edison) is a leading international investment research company. Edison and its subsidiaries (Edison Group) have won industry recognition, with awards both in Europe and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison's research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York, Sydney and Wellington. Edison is authorised and regulated by the United Kingdom's Financial Services Authority ([www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584](http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584)). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only.

**DISCLAIMER**

Copyright 2012 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Primary Health Properties and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c)(1)(a), (b) and (c) of the FAA). It is not intended for retail clients. This is not a solicitation or inducement to buy, sell, subscribe, or underwrite securities. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct an investment business and, accordingly, does not hold any positions in the securities mentioned in this report. However, their respective directors, officers, employees and contractors may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication.

Registered in England, number 4794244, Edison Investment Research Limited is authorised and regulated by the United Kingdom Financial Services Authority, [www.edisoninvestmentresearch.co.uk](http://www.edisoninvestmentresearch.co.uk). Registered on the New Zealand Financial Service Providers Register, number 247505, Edison Investment Research (NZ) Limited is registered to provide wholesale and/or generic financial adviser services and is regulated by the New Zealand Financial Markets Authority.

**London** +44 (0)20 3077 5700  
Lincoln House, 296-302 High Holborn  
London, WC1V 7JH, UK

**New York** +1 646 653 7026  
245 Park Avenue, 24<sup>th</sup> Floor 10167,  
New York, US

**Wellington** +64 4894 8555  
Level 15 HP Tower, 171 Featherston  
Street, Wellington 6011, NZ

**Sydney** +61 (0)2 9258 1162  
Level 33, Australia Square, 264 George St,  
Sydney, NSW 2000, Australia